# CC-95266-MM-001 (NCT04674813)

> A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04674813
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Juno Therapeutics, a Subsidiary of Celgene
- Conditions: Multiple Myeloma
- Interventions: CC-95266; Fludarabine; Cyclophosphamide; Bendamustine
- Enrollment: 130
- Primary outcome: Number of participants with Adverse Events (AEs)
- Primary outcome: Number of participants with significant laboratory abnormalities
- Primary outcome: Number of participants with Dose Limiting Toxicities (DLTs)
- Primary outcome: Maximum Tolerated Dose (MTD)
- Primary outcome: Recommended Phase 2 Dose (RP2D)

## Indexed commentary on CC-95266-MM-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cc-95266-mm-001-nct04674813